EPS for Johnson and Johnson (JNJ) Expected At $ 1.72

EPS for Johnson and Johnson (JNJ) Expected At
 $ 1.72

January 14, 2018 – By Adrian Mccoy

Investors sentiment is 0.83 in 2017 Q3. Its the same as in 2017Q2. It is the same, as 45 investors sold Johnson & Johnson shares while 871 reduced holdings. only 111 funds opened positions while 645 raised stakes. 1.71 billion shares or 0.90% less than 1.73 billion shares in 2017Q2 were reported. Ironwood Investment Counsel Limited Liability Com holds 3.41% or 64.725 shares. Fairview Capital Inv Mngm Ltd Ltd Liability Com reported 285,887 shares. Ing Groep Nv accumulated 676,388 shares. Comgest Glob Invsts Sas accumulated 36,600 shares or 0.11% of the stock. Gamble Jones Inv Counsel reported 203,797 shares. Capital Mngmt Assocs New York invested in 2,100 shares or 0.39% of the stock. Granite Inv Partners Limited Liability Corp. stated it has 66,815 shares. Schmidt P J Inv Management Incorporated stated it has 61,577 shares or 2.4% of all its holdings. Paw Cap Corp holds 0.75% of its portfolio in Johnson & Johnson (NYSE: JNJ) for 5,500 shares. Summit Financial Wealth Advisors Llc holds 0.12% or 2,637 shares in its portfolio. St Germain D J accumulated 2.38% gold 145,938 shares. Mckinley Capital Mgmt Limited Liability Company Delaware 1.96% of its portfolio in Johnson & Johnson (NYSE: JNJ). Dupont Capital Mgmt Corp. has 265,295 shares or 0.78% of all its holdings. Oppenheimer Asset Mngmt Inc. invested in 525,084 shares. First Wilshire Management, a California-based fund reported 2,553 shares.
Analysts expect Johnson & Johnson (NYSE: JNJ) to report $ 1.72 EPS on January, 23.They anticipates $ 0.14 EPS change or 8.86% from last quarter’s $ 1.58 EPS. JNJ’s profit would be $ 4.62B giving it 21.19 P / E if the $ 1.72 EPS is ok. After having $ 1.90 EPS previously, Johnson & Johnson’s analysts see -9.47% EPS growth. The stock increased 0.67% or $ 0.97 during the last trading session, reaching $ 145.76. About 5.45 million shares traded. Johnson & Johnson (NYSE: JNJ) has risen 12.54% since January 14, 2017 and is uptrending. It has underperformed by 4.16% the S & P500.

Johnson & Johnson (NYSE: JNJ) Ratings Coverage
Among 23 analysts covering Johnson & Johnson ( NYSE: JNJ ), 12 have Buy rating, 5 Sell and 6 Hold. Therefore 52% are positive. Johnson & Johnson has $ 165 highest and $ 90 lowest target. $ 136.94’s average price is -6.05% below $ 145.76 stock price. Johnson & Johnson had 84 analyst reports since August 7, 2015 according to SRatingsIntel. On Wednesday, October 8th, 2009 RBC Capital Markets with “Outperform”. The firm has “Buy” rating given on Monday, July 10 by RBC Capital Markets. The firm has “Equal-Weight” rating by Barclays Capital given on Wednesday, October 18. UBS maintained the stock with “Buy” rating in Wednesday, October 19 report. The rating is maintained by BMO Capital Markets on Monday, July 10 with “Buy”. The firm has “Buy” rating given on Wednesday, October 18 by Wells Fargo. The stock of Johnson & Johnson (NYSE: JNJ) has “Hold” rating given on Tuesday, September 13 by Jefferies. RBC Capital Markets maintained with “Buy” rating and $ 144.0 target in Friday, September 22 report. Argus Research maintained with “Buy” rating and $ 130 target in Wednesday, April 20 report. The firm has “Hold” rating by Jefferies given on Tuesday, August 15.
Johnson & Johnson, together with its subsidiaries, researches and develops, makes and sells various products in the health care field worldwide. The company has market cap of $ 391.59 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices. It has a 25.35 P / E ratio. The consumer segment offers baby care products under the JOHNSON’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, THE SMALL MARSEILLE, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

More notable recent Johnson & Johnson (NYSE: JNJ) news were published by: Seekingalpha.com which released: “Johnson & Johnson: A Good Value In This Overheated Market” on January 08, 2018, also Fool.com with their article: ” Johnson & Johnson Wants to Create a Crisis – and That’s Great for Investors “published on January 09, 2018, Seekingalpha.com published:” Johnson & Johnson (JNJ) Presents Management at 36th Annual JPMorgan Healthcare … “on January 09, 2018. More Johnson & Johnson (NYSE: JNJ) was released by: Fool.com and their article: “Better Stock: AbbVie Inc (ABBV). Johnson & Johnson (JNJ) “published on January 10, 2018 Cnbc.com’s news article titled:” Young immigrant who works for Johnson & Johnson pleads with lawmakers and CEO … “with publication date: January 11, 2018.

Receive News & Ratings Via Email – Enter your email address below to receive a daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Post Comment